ANAVEX LIFE SCIENCES CORP.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
AVXLANAVEX LIFE SCIENCES CORP. · Stock |
Sale $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Christopher L. JacobsHouse · R · NY |
AVXLANAVEX LIFE SCIENCES CORP. · Stock |
Purchase $1,001 - $15,000 |
Nov 16, 2022 | Oct 12, 2022 | Filing ↗ |
Whale Activity
- Increased42
- New15
- Held36
- Decreased68
- Closed24
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 8.1M | $16.5M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1M | $8.3M | increased |
| GMT CAPITAL CORP | 2.7M | $5.5M | new |
| FEDERATED HERMES, INC. | 2.6M | $5.2M | increased |
| TWO SIGMA INVESTMENTS, LP | 2.3M | $4.7M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3M | $4.6M | decreased |
| STATE STREET CORP | 2.0M | $4.0M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 898.5K | $1.8M | decreased |
| Summit Financial, LLC | 889.1K | $1.8M | decreased |
| GOLDMAN SACHS GROUP INC | 889.1K | $1.8M | decreased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 887.0K | $1.8M | increased |
| BARCLAYS PLC | 868.3K | $1.8M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| MISSLING CHRISTOPHER UPresident and CEO · Director | Tax withholding | −145.0K | $9.58 | $1.4M | Sep 11, 2025 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +187.5K | $5.04 | $945K | Sep 11, 2025 | Form 4 ↗ |
| Thomas SteffenDirector | Tax withholding | −11.3K | $7.75 | $88K | Jun 5, 2025 | Form 4 ↗ |
| Thomas SteffenDirector | Option exercise | +50.0K | $1.76 | $88K | Jun 5, 2025 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Tax withholding | −282.5K | $9.63 | $2.7M | Mar 24, 2025 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +500.0K | $0.92 | $460K | Mar 24, 2025 | Form 4 ↗ |
| Donhauser Peter D.O.Director | Purchase | +2,835 | $3.64 | $10K | Jun 14, 2024 | Form 4 ↗ |
| Thomas SteffenDirector | Purchase | +5,000 | $4.52 | $23K | May 15, 2024 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Sale | −73.4K | $5.11 | $375K | Mar 28, 2024 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +73.4K | $1.32 | $97K | Mar 28, 2024 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +232.0K | $1.60 | $371K | Jun 29, 2023 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Sale | −268.0K | $7.98 | $2.1M | Jun 28, 2023 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +268.0K | $1.60 | $429K | Jun 28, 2023 | Form 4 ↗ |
| Skarpelos AthanasiosDirector | Sale | −50.0K | $9.06 | $453K | May 25, 2022 | Form 4 ↗ |
| Skarpelos AthanasiosDirector | Option exercise | +50.0K | $0.92 | $46K | May 25, 2022 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Sale | −51.6K | $26.00 | $1.3M | Jun 29, 2021 | Form 4 ↗ |
| MISSLING CHRISTOPHER UPresident and CEO · Director | Option exercise | +51.6K | $1.32 | $68K | Jun 29, 2021 | Form 4 ↗ |
| Boenisch SandraPFO and Treasurer | Sale | −166.7K | $26.53 | $4.4M | Jun 29, 2021 | Form 4 ↗ |
| Boenisch SandraPFO and Treasurer | Option exercise | +35.0K | $5.92 | $207K | Jun 29, 2021 | Form 4 ↗ |
| Boenisch SandraPFO and Treasurer | Option exercise | +106.7K | $3.28 | $350K | Jun 29, 2021 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $7.6M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.4M | $6.3M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund Federated Hermes MDT Series | 2.0M | $5.6M | 0.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.0M | $2.8M | 0.01% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.0M | $2.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 737.5K | $1.9M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 631.7K | $1.6M | 0.02% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 528.0K | $1.5M | 0.01% | Aug 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 436.3K | $1.2M | 0.01% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 398.0K | $1.1M | 0.00% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list AVXL's shares (CUSIP 032797300), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 4.7M shares5.0%
Jul 31, 2026 · ↗
Corporate Lobbying
Government Contracts
No federal contract awards found for ANAVEX LIFE SCIENCES CORP..
U.S. Patents
No USPTO patent applications found for ANAVEX LIFE SCIENCES CORP..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M |
| Diluted EPS | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 |
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M |
| Cash and equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M |
| Shareholders' equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M |
As ANAVEX LIFE SCIENCES CORP. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Nov 25, 2025 ↗
Stock Splits
- 1-for-4Reverse splitOct 7, 2015
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 5.02, 9.01Officer / director changeNov 3, 2026
EDGAR ↗ - 8-K · Items 5.02, 8.01, 9.01Officer / director change · Other eventsNov 2, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 20, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 15, 2026
EDGAR ↗ - 8-K · Items 5.01, 5.07Change in control · Shareholder voteSep 28, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 9, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 17, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 11, 2026
EDGAR ↗
About ANAVEX LIFE SCIENCES CORP.
Overview and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials. The Company’s focus is on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Our research and development pipeline includes ANAVEX®2-73 currently in thre…

